Monitoring of Aspirin Therapy in Patients with Cerebrovascular Pathology
Open Access
- 3 September 2021
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (4), 537-543
- https://doi.org/10.20996/1819-6446-2021-08-15
Abstract
Aim. Evaluation of various methods for determining the effectiveness of aspirin therapy and aspirin resistance in patients with cerebrovascular disease (CVD) depending on the presence of type 2 diabetes mellitus (T2DM). Materials and methods. The prospective study included 78 patients with various manifestations of CVD. All patients received acetylsalicylic acid (ASA) 75 mg daily. Along with a comprehensive clinical examination, a laboratory assessment of platelet function with the usage of Born method with aggregometer, a detailed biochemical blood test (including the determination of the small subunit of low density lipoprotein [s-LDL]), as well as therapeutic drug monitoring of salicylates were performed on a gas chromatograph-mass spectrometer. Results. In 53% of cases, the absence or insufficiency of the effect of ASA on platelet aggregation was noted. Two subgroups were separately identified: with T2DM; (n=40) and without T2DM (n=38). Insufficient effect of the drug on platelet aggregation characteristics were observed in 65% of patients with T2DM and in 38% without T2DM. The differences were revealed between the groups in triglycerides, s-LDL, glycemic and glycated hemoglobin (p Conclusion. It is advisable to monitor aspirin therapy both with the assessment of platelet aggregation and with therapeutic drug monitoring. The relationship between the level of ASA and SA in the blood plasma and the functional activity of platelets was confirmed. The presence of T2DM is associated with a decrease in the concentration of ASA and aspirin resistance detected in therapeutic drug monitoring.Keywords
This publication has 16 references indexed in Scilit:
- Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational ApproachCurrent Atherosclerosis Reports, 2018
- ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetesAmerican Heart Journal, 2017
- Aspirin Resistance: Clinical and Molecular Genetic Evaluation TechniquesHuman Physiology, 2017
- Monitoring Antiplatelet TherapySeminars in Thrombosis and Hemostasis, 2017
- The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with AspirinPLOS ONE, 2015
- European Stroke Conference. 23rd Conference, Nice, France, May 6–9, 2014: Abstract e-BookCerebrovascular Diseases, 2014
- Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasmaEuropean Journal of Clinical Pharmacology, 2013
- Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion VolumesJournal of the American College of Cardiology, 2011
- Aspirin resistanceThe Lancet, 2006
- Aggregation of Blood Platelets by Adenosine Diphosphate and its ReversalNature, 1962